Forte Biosciences (FBRX) Assets Average (2017 - 2026)

Forte Biosciences (FBRX) has 10 years of Assets Average data on file, last reported at $75.0 million in Q1 2026.

• On a quarterly basis, Assets Average rose 37.59% year-over-year to $75.0 million in Q1 2026; TTM through Mar 2026 was $75.0 million, a 37.59% increase from a year earlier, with the FY2025 full-year figure at $72.2 million, up 43.56% from the prior year.
• Assets Average for Q1 2026 stood at $75.0 million, down from $89.9 million in the prior quarter.
• Over the last five years, Assets Average for FBRX reached as high as $102.4 million in Q3 2025 and fell as low as $22.0 million in Q3 2024.
• Historically, Assets Average has averaged $50.1 million across 5 years, with a median of $42.3 million in 2022.
• Across the five-year window, Assets Average plunged 44.32% in 2024 and jumped 365.36% in 2025, its largest moves.
• Year by year, Assets Average stood at $43.6 million in 2022, then dropped by 0.31% to $43.4 million in 2023, then declined by 8.46% to $39.8 million in 2024, then surged by 126.23% to $89.9 million in 2025, then slipped by 16.6% to $75.0 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $75.0 million in Q1 2026, $89.9 million in Q4 2025, and $102.4 million in Q3 2025.